[1]
Ribeiro, P.; Fiorino, G.; Danese, S. The Experience with biosimilars of infliximab in inflammatory bowel disease. Curr. Pharm. Des., 2017, 23(44), 6759-6769.
[2]
Michetti, P. Efficacy of infliximab biosimilars in patients with Crohn’s disease. Lancet, 2017, 390(10111), 2435.
[3]
Martelli, L.; Peyrin-Biroulet, L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review. Curr. Med. Chem., 2019, 26(2), 270-279.
[4]
Magro, F.; Coelho, R.; Peixoto, A. Can we extrapolate data from one immune-mediated inflammatory disease to another one? Curr. Med. Chem., 2019, 26(2), 248-258.